Regen BioPharma Reports $239 Cash, Massive Dilution, and Going Concern Doubt
Summary
Regen BioPharma's Q3 10-Q shows cash of just $239, massive share dilution from convertible debt conversions, and a going concern warning. Subsequent events include issuance of hundreds of millions more shares and a new super-voting preferred stock for the CEO.
Key Events · Earnings and Guidance · RGBP
-
Cash Collapses to $239
Cash fell from $69,555 at September 30, 2025 to $239 at June 30, 2026. The company used $285,244 in operating activities during the nine months.
-
Massive Dilution from Convertible Debt
During the nine months ended June 30, 2026, the company issued 836,299,355 common shares for $306,492 of debt, 67,557,264 shares for $37,897 of interest, and 116,465,570 shares for $30,500 of fees. In Q3 alone, 640,234,604 shares were issued for $100,179 of debt.
-
Going Concern Warning
Management states substantial doubt about the company's ability to continue as a going concern. Accumulated deficit is $22.3 million and working capital deficit is approximately $5.9 million.
-
Subsequent Events Show Continued Dilution
After June 30, 2026, the company issued 110,000,000 shares on August 11, 2026, 130,000,000 on July 31, 2026, and over 300 million more shares in July 2026 for small amounts of debt.
Analysis · RGBP · Life Sciences
Regen BioPharma's Q3 10-Q reveals a company on the brink. Cash has collapsed to $239, down from $69,555 nine months ago. The company issued over 1.1 billion common shares during the nine months ended June 30, 2026, primarily to satisfy convertible debt at deeply discounted prices. Subsequent events show continued massive dilution: 110 million shares issued on August 11, 2026 alone. The company explicitly states substantial doubt about its ability to continue as a going concern. The creation of Series N Preferred Stock with 75 million votes per share, issued to CEO David Koos, raises serious governance concerns. This is a critical distress signal for existing shareholders.
At the time of this filing, RGBP was trading at $0.00 on OTC in the Life Sciences sector, with a market capitalization of approximately $143.5K. The 52-week trading range was $0.00 to $0.05. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.